High miR-126-3p levels associated with cardiovascular events in a general population

• Published in: European journal of internal medicine Vol. 113; pp. 49 - 56
• Main Authors: Martinez-Arroyo, Olga, Ortega, Ana, Flores-Chova, Ana, Sanchez-Garcia, Belen, Garcia-Garcia, Ana B, Chaves, Felipe J, Martin-Escudero, Juan C, Forner, Maria Jose, Redon, Josep, Cortes, Raquel
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2023; Elsevier Science
• Subjects: Albuminuria; Biomarker; Biomarkers; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - genetics; Cardiovascular event; Cardiovascular risk; Endothelial dysfunction; Humans; Hypertension - epidemiology; MicroRNA; MicroRNAs - genetics; Original; Retrospective Studies; Stroke; Endothelial dysfunction; Cardiovascular event; Biomarker; MicroRNA; Albuminuria; Cardiovascular risk
• ISSN: 0953-6205; 1879-0828
• DOI: 10.1016/j.ejim.2023.04.013

•A renewed interest exists in miRNAs as biomarkers in cardiovascular disease.•miR-126–3p is associated with albuminuria, a marker of endothelial dysfunction, in hypertension.•High miR-126–3p levels are associated with cardiovascular events in general population. Endothelial dysfunction is a forerunner of atherosclerosis, leading to cardiovascular disease, and albuminuria is a marker of endothelial dysfunction. Circulating levels of microRNAs are emerging as potential biomarkers for cardiovascular disease. Here we estimate the predictive value of a plasma microRNAs signature associated with albuminuria in the incidence of cardiovascular events. Plasma microRNAs quantified in hypertensive patients by next generation sequencing were validated in a cohort of patients and controls by real-time quantitative PCR. The microRNAs found to be associated with albuminuria were analysed for their prognostic value in predicting cardiovascular events incidence on a retrospective, population-based study (Hortega Study), using Cox proportional hazard models. A plasma microRNA profile was identified in the discovery cohort (n = 48) associated with albuminuria and three microRNAs (miR-126–3p, miR-1260b and miR-374a-5p) were confirmed in the validation cohort (n = 98). The microRNA signature discriminates urinary albumin excretion at baseline (n = 1025), and predicts the incidence of cardiovascular events and coronary heart disease and stroke in a general population retrospective study within a 14-year follow-up (n = 926). High miR-126–3p levels were associated with a shorter time free of both cardiovascular events (HR=1.48, (1.36–1.62), p < 0.0001), as well as coronary artery disease and stroke combined (HR=2.49, (2.19–2.83), p < 0.0001). An increased plasma microRNAs profile was identified in hypertensive patients with albuminuria. Increased miR-126–3p suggest it may serve as a prognostic marker for cardiovascular events in a long-term general population. Further studies will assess the potential role of miR-126–3p as a guide for the status of endothelial dysfunction. Circulating miR-126–3p as a prognostic marker of MACE and combined CAD and stroke in a long-term general population cohort. A signature of 4 miRNAs is associated with albuminuria in the discovery and validation cohorts of hypertensive patients and controls. in a general population cohort (Hortega testing cohort) followed during 14 years, increased levels of plasma circulating miR-126–3p are associated with the incidence of MACE (major adverse cardiovascular events) and combined CAD (coronary artery disease) and stroke. [Display omitted]